Lundbeck has great expectations for new antibody: "This could be the new generation of migraine drugs"
The pharmaceutical firm thinks Lu AG0922 could be the backbone of a new generation of migraine treatments and has launched several studies in the hope of targeting a broader indication, Head of R&D at Lundbeck Johan Luthman tells MedWatch.
by ALBERT RØNNING-ANDERSSON, translated by daniel pedersen
Pharmaceutical firm Lundbeck's Laboratories are buzzing, busy with the work spearheaded by the company's Head of Research and Development Johan Luthman, as a new generation of migraine drugs are taking shape.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck hunts for new success drugs in niche diseases
For subscribers
